Milla Juutinen

Milla Juutinen

Auto-generated profile, based on publicly available information

Milla Juutinen

Faculty of Medicine and Health Technology, Tampere University

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MJMilla Juutinen
Milla Juutinen
CWCassia Wang
Cassia Wang
JZJustin Zhu
Justin Zhu
JHJuan Haladjian
Juan Haladjian
JRJari Ruokolainen
Jari Ruokolainen
AVAntti Vehkaoja
Antti Vehkaoja
Parkinson’s disease (PD) is a neurodegenerative disease inducing dystrophy of the motor system. Automatic movement analysis systems have potential in improving patient care by enabling personalized and more accurate adjust of treatment. These systems utilize machine learning to classify the movement properties based on the features derived from the signals. Smartphones can provide an inexpensive measurement platform with their built-in sensors for movement assessment. This study compared three feature selection and nine classification methods for identifying PD patients from control subjects based on accelerometer and gyroscope signals measured with a smartphone during a 20-step walking test. Minimum Redundancy Maximum Relevance (mRMR) and sequential feature selection with both forward (SFS) and backward (SBS) propagation directions were used in this study. The number of selected features was narrowed down from 201 to 4–15 features by applying SFS and mRMR methods. From the methods compared in this study, the highest accuracy for individual steps was achieved with SFS (7 features) and Naive Bayes classifier (accuracy 75.3%), and the second highest accuracy with SFS (4 features) and k Nearest neighbours (accuracy 75.1%). Leave-one-subject-out cross-validation was used in the analysis. For the overall classification of each subject, which was based on the majority vote of the classified steps, k Nearest Neighbors provided the most accurate result with an accuracy of 84.5% and an error rate of 15.5%. This study shows the differences in feature selection methods and classifiers and provides generalizations for optimizing methodologies for smartphone-based monitoring of PD patients. The results are promising for further developing the analysis system for longer measurements carried out in free-living conditions.

4 February 2024 in International Journal of Medical Informatics
Verified
Journal Article
Open access
AKAntti Kallonen
Antti Kallonen
MJMilla Juutinen
Milla Juutinen
Alpo VärriAlpo Värri
Alpo Värri
GCGuy Carrault
Guy Carrault
PPPatrick Pladys
Patrick Pladys
ABAlain Beuchée
Alain Beuchée
Neonatal sepsis is responsible for significant morbidity and mortality worldwide. Its accurate and timely diagnosis is hindered by vague symptoms and the urgent necessity for early antibiotic intervention. The gold standard for diagnosing the condition is the identification of a pathogenic organism from normally sterile sites via laboratory testing. However, this method is resource-intensive and cannot be conducted continuously. This study aimed to predict the onset of late-onset sepsis (LOS) with good diagnostic value as early as possible using non-invasive biosignal measurements from neonatal intensive care unit (NICU) monitors. In this prospective multicenter study, we developed a multimodal machine learning algorithm based on a convolutional neural network (CNN) structure that uses the power spectral density (PSD) of recorded biosignals to predict the onset of LOS. This approach aimed to discern LOS-related pathogenic spectral signatures without labor-intensive manual artifact removal. The model achieved an area under the receiver operating characteristic score of 0.810 (95 % CI 0.698-0.922) on the validation dataset. With an optimal operating point, LOS detection had 83 % sensitivity and 73 % specificity. The median early detection was 44 h before clinical suspicion. The results highlighted the additive importance of electrocardiogram and respiratory impedance (RESP) signals in improving predictive accuracy. According to a more detailed analysis, the predictive power arose from the morphology of the electrocardiogram's R-wave and sudden changes in the RESP signal. Raw biosignals from NICU monitors, in conjunction with PSD transformation, as input to the CNN, can provide state-of-the-art prediction performance for LOS without the need for artifact removal. To the knowledge of the authors, this is the first study to highlight the independent and additive predictive potential of electrocardiogram R-wave morphology and concurrent, sudden changes in the RESP waveform in predicting the onset of LOS using non-invasive biosignals.

5 May 2025 in Finnish Journal of eHealth and eWelfare
Verified
Journal Article
Open access
PDF file
MJMilla Juutinen
Milla Juutinen
JRJari Ruokolainen
Jari Ruokolainen
JPJuha Puustinen
Juha Puustinen
AHAnu Holm
Anu Holm
MGMark Van Gils
Mark Van Gils
AVAntti Vehkaoja
Antti Vehkaoja
Parkinson's disease is a neurodegenerative disorder that affects mobility, leading to a decline in the patient's quality of life. Analyzing gait for these patients aims to improve the mobility of the Parkinson’s disease patients. The goal of this study was to validate mean amplitude deviation for detecting gait in Parkinson’s disease patients and healthy controls. This method is robust and orientation-independent and has accurate results on physical activity detection for different study populations. The novelty of this study is to use and evaluate a previously validated method with Parkinson’s disease patients instead of healthy young subjects as in earlier studies. We utilized inertial measurement unit data measured using smartphones from pre-existing datasets with pre-defined and labeled activities and free-living data containing continuously collected over three consecutive days. One dataset included 30 healthy adults, and the other two included in total of 62 and 68 Parkinson’s disease patients and 40 and 39 healthy controls, respectively. The sensitivity of the algorithm in a controlled measurement setting was 100% and 98.7% for healthy adults and a combined dataset of Parkinson’s disease patients and control subjects, respectively. Correspondingly, the specificity was 74.9% and 81.6%. Visual inspection of the free-living data showed that the algorithm provided durations and timings of walking activities, and walking took place during the daytime as anticipated for subjects with a typical daily rhythm. Median walking times were under ten minutes per hour. The results reached the same performance range as earlier studies with an orientation-independent approach, justifying the feasibility of this method. Therefore, this study validated the use of mean amplitude deviation for walking detection in Parkinson’s disease patients and healthy adults. Future research will utilize the detected walking segments in analyzing the motor symptoms of the disease aiming to improve patient well-being through identifying the needs for additional healthcare interventions.

13 November 2018 in JMIR Preprints
Verified
Preprint
Open access
MJMilla Jauhiainen
Milla Jauhiainen
JPJuha Puustinen
Juha Puustinen
SMSaeed Mehrang
Saeed Mehrang
JRJari Ruokolainen
Jari Ruokolainen
AHAnu Holm
Anu Holm
HNHannu Nieminen
Hannu Nieminen
BACKGROUND Clinical characterization of motion in patients with Parkinson disease (PD) is challenging: symptom progression, suitability of medication, and level of independence in the home environment can vary across time and patients. Appointments at the neurological outpatient clinic provide a limited understanding of the overall situation. In order to follow up these variations, longer-term measurements performed outside of the clinic setting could help optimize and personalize therapies. Several wearable sensors have been used to estimate the severity of symptoms in PD; however, longitudinal recordings, even for a short duration of a few days, are rare. Home recordings have the potential benefit of providing a more thorough and objective follow-up of the disease while providing more information about the possible need to change medications or consider invasive treatments. OBJECTIVE The primary objective of this study is to collect a dataset for developing methods to detect PD-related symptoms that are visible in walking patterns at home. The movement data are collected continuously and remotely at home during the normal lives of patients with PD as well as controls. The secondary objective is to use the dataset to study whether the registered medication intakes can be identified from the collected movement data by looking for and analyzing short-term changes in walking patterns. METHODS This paper described the protocol for an observational case-control study that measures activity using three different devices: (1) a smartphone with a built-in accelerometer, gyroscope, and phone orientation sensor, (2) a Movesense smart sensor to measure movement data from the wrist, and (3) a Forciot smart insole to measure the forces applied on the feet. The measurements are first collected during the appointment at the clinic conducted by a trained clinical physiotherapist. Subsequently, the subjects wear the smartphone at home for 3 consecutive days. Wrist and insole sensors are not used in the home recordings. RESULTS Data collection began in March 2018. Subject recruitment and data collection will continue in spring 2019. The intended sample size was 150 subjects. In 2018, we collected a sample of 103 subjects, 66 of whom were diagnosed with PD. CONCLUSIONS This study aims to produce an extensive movement-sensor dataset recorded from patients with PD in various phases of the disease as well as from a group of control subjects for effective and impactful comparison studies. The study also aims to develop data analysis methods to monitor PD symptoms and the effects of medication intake during normal life and outside of the clinic setting. Further applications of these methods may include using them as tools for health care professionals to monitor PD remotely and applying them to other movement disorders. CLINICALTRIAL ClinicalTrials.gov NCT03366558; https://clinicaltrials.gov/ct2/show/NCT03366558 INTERNATIONAL REGISTERED REPOR DERR1-10.2196/12808